Lemtrada May Slow MS Disease Progression, Long-term Study Suggests

Lemtrada May Slow MS Disease Progression, Long-term Study Suggests

282543

Lemtrada May Slow MS Disease Progression, Long-term Study Suggests

Lemtrada (alemtuzumab) may slow the progression of multiple sclerosis (MS) and lower the conversion rate of relapsing-remitting MS (RRMS) to secondary progressive MS (SPMS), a long-term study suggests. The results showed that patients converting to SPMS — in which a person’s disability gets steadily worse — were older, had longer disease duration, and had greater brain lesions. The study, “Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years,”…

You must be logged in to read/download the full post.